| Document |
Document Title |
|
WO/2019/207026A1 |
A composition for treating one or more estrogen related diseases Abstract The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency relat...
|
|
WO/2019/202142A1 |
The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units,for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an...
|
|
WO/2019/201713A1 |
The present invention relates to a therapeutically active compound for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring. ...
|
|
WO/2019/202141A1 |
The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units,for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an...
|
|
WO/2019/196728A1 |
Disclosed in the present invention is an application for an oestrogen receptor down-regulator, relating to the technical field of medicine. To solve the problem in the prior art of the relatively few types of oestrogen receptor down-regu...
|
|
WO/2019/194217A1 |
A monoclonal antibody produced by an established hybridoma expresses high selectivity for IL-18, and is also capable of performing western blotting, immunoprecipitation and immunostaining that are important for analyzing functions of IL-...
|
|
WO/2019/193342A1 |
The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates...
|
|
WO/2019/186516A1 |
Cinacalcet is approved and marketed as hydrochloride salt in a solid dosage form indicated for the treatment of secondary hyperparathyroidism resulting from chronic kidney disease and for the treatment of hypercalcemia in patients with e...
|
|
WO/2019/183835A1 |
Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound 1 and its salts (such as sodium, potassium, and calcium salt), as well as methods of pr...
|
|
WO/2019/185881A1 |
The present invention relates to compositions comprising: (a) a biodegradable polymer; (c) an alkyl ammonium EDTA salt comprising an anion of ethylenediaminetetraacetic acid or an analogue thereof, dissolved or dispersed in said biodegra...
|
|
WO/2019/190965A1 |
Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism,...
|
|
WO/2019/182981A1 |
The present invention is directed to a method for preventing and/or treating melanoma such as superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. The method comprises administering ...
|
|
WO/2019/176239A1 |
Provided are: a medicinal preparation comprising a liquid medicinal composition that contains human PTH (1-34) (teriparatide) as an active ingredient and has a high storage stability; and a method for manufacturing the same. The present ...
|
|
WO/2019/174990A1 |
New soft capsules are described having within them a fill comprising thyroid hormones (thyroxine T4 or triiodothyronine T3) and a high amylose-starch, optionally associated with vegetable hydrocolloids and/or glycerol. Compared to tradit...
|
|
WO/2019/177163A1 |
This application provides: a novel mouse artificial chromosome vector that is stable in rodent cells or tissues or rodent individuals, specifically a mouse artificial chromosome vector derived from a mouse chromosome selected from the gr...
|
|
WO/2019/177902A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of Burton's Tyrosine Kinase (BTK). In particular, the present disclosure is directed to bifunctional compounds. One end of a bifunctional compound...
|
|
WO/2019/171377A1 |
The present disclosure provides compositions and methods for providing a cell replacement therapy to treat various diseases, including pancreatic diseases and diabetes. Specifically, the disclosure provides three-dimensional (3D) cell cl...
|
|
WO/2019/173224A1 |
The present disclosure provides compounds that modulate protein function and/or restore protein homeostasis. The disclosure provides methods of modulating protein-mediated diseases, disorders, conditions, or responses. Compositions, incl...
|
|
WO/2019/168324A1 |
The present invention relates to a composition for preventing and treating hormonal disorders or andropause in males, containing, as an active ingredient, a herbal medicine extract comprising a combination of compounds comprising flavono...
|
|
WO/2019/169089A1 |
Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
|
|
WO/2019/166984A1 |
The subject matter of the invention is a composition containing myo-inositol and D-chiro-inositol for use in method of weight reduction, improvement of metabolic and hormonal parameters and improvement of condition of skin in women with ...
|
|
WO/2019/162425A1 |
The present invention relates to a glycan composition useful as nutritional supplement, such as for infant formula supplement and as nutraceutical products and a method of preparation thereof.
|
|
WO/2019/154237A1 |
The present invention relates to a co-crystal of calcifediol and vitamin D3, a preparation method therefor and use thereof. In the co-crystal, the molar ratio of calcifediol to vitamin D3 is 1: 1. The co-crystal of calcifediol and vitami...
|
|
WO/2019/156199A1 |
The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune d...
|
|
WO/2019/151353A1 |
A method for producing a preparation for injection, said method comprising: a first step for performing at least one treatment selected from the group consisting of a treatment whereby benzyl benzoate is mixed with an antioxidant, a trea...
|
|
WO/2019/151883A1 |
The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and ...
|
|
WO/2019/149178A1 |
The present invention relates to a glucopyranosyl derivative and a use thereof. In particular, the present invention relates to a glucopyranosyl derivative that is used as an inhibitor of sodium-dependent glucose transporters (SGLTs), pa...
|
|
WO/2019/147718A1 |
Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery. Current therapeutic options have suboptimal efficacy. Small doses of stable liquid glucagon can be used to treat or prevent post-bari...
|
|
WO/2019/146612A1 |
The present invention provides an excellent composition (e.g., a drug, a quasi drug, a cosmetic) for skin diseases treatment use. The composition for skin diseases treatment use according to the present invention contains an exosome secr...
|
|
WO/2019/144835A1 |
The present invention relates to a pharmaceutical composition of a substituted pyridazinone compound and use thereof. The substituted pyridazinone compound is a compound as represented by formula (I), or a pharmaceutically acceptable sal...
|
|
WO/2019/137138A1 |
The present invention relates to a use of human GPNMB protein or an antagonist or agonist thereof. It has been found that GPNMB gene, RNA, and protein can be used as biomarkers for diagnosing a metabolic disease, such as obesity, diabete...
|
|
WO/2019/131998A1 |
The present invention addresses the problem of providing an astatine solution that can be used in radionuclide therapy for the treatment of thyroid disease or the like, and a method for producing the same. The present invention provides:...
|
|
WO/2019/131458A1 |
Provided are a compound represented by formula (1) or a salt thereof, and a medicine including the same. [In the formula, X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represent...
|
|
WO/2019/120079A1 |
The present invention provides a thioxoimidazole dione compound as shown in formula (I). The compound can act as an androgen receptor antagonist and can be used to prepare a drug for treating an androgen receptor-related disease or disor...
|
|
WO/2019/124411A1 |
A medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis, said medicinal composition comprising 3-{[(2S)-2-amino-2-carboxyethyl]carmaboylamino}-5-chloro-4-m
ethylbenzenesulfonic acid or ...
|
|
WO/2019/123427A1 |
Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.
|
|
WO/2019/109124A1 |
There is provided compositions and methods for modulating the fenestration porosity, fenestration frequency or fenestration diameter of liver endothelial cells. In particular compositions comprising conjugates of quantum dots and a thera...
|
|
WO/2019/104391A1 |
The present invention relates to peptides, compositions and methods for the treatment, prevention or monitoring the progression of type 1 diabetes.
|
|
WO/2019/104748A1 |
Disclosed is the use of the compound as shown in formula Ⅰ or a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof in preparing dr...
|
|
WO/2019/103129A1 |
The present invention addresses the problem of providing a technique for efficiently producing a cell mass including pituitary tissue from pluripotent stem cells. A method for producing a cell mass including pituitary tissue, the method ...
|
|
WO/2019/104225A1 |
Provided herein are microspheres (e.g., single emulsion microspheres) comprising a therapeutic compound or pharmaceutically acceptable salt thereof, one or more polymers, and optionally a polyol, as well as methods of preparation, method...
|
|
WO/2019/101035A1 |
A glucagon analogue for treating metabolic diseases, the structure formula is as follows: H-X2-X3-GTFTSD-X10-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz or H-S-Q-GTFTSD-Y-SKYLD-X16-X17-AAQ-DFVQWLMN-X29-Xz-NH2. The described glucagon analogue has a...
|
|
WO/2019/100503A1 |
The present invention provides a use of an agent for preparing a medicament for inhibiting microRNA-708. The medicament is used for at least one of the following: reducing intracellular triglyceride content, inhibiting differentiation of...
|
|
WO/2019/095027A1 |
The field of application is the pharmaceutical industry and the area of medicinal formulations for transdermal administration. Use of drugs with a molar mass below 500 that are soluble in propylene glycol and specifically the drugs testo...
|
|
WO/2019/098238A1 |
Provided is an activator for a peroxisome proliferator-activated receptor α which contains: a compound represented by general formula (I); a tautomer, stereoisomer, or pharmaceutically acceptable salt of said compound; or a solvate of a...
|
|
WO/2019/099725A1 |
Disclosed herein are compositions and methods useful for manufacturing SC- cell, and isolated populations of SC- cells for use in various applications, such as cell therapy.
|
|
WO/2019/092449A1 |
The present invention relates to a construct comprising a C13 to C27 fatty acid non- covalently bound to a hydrophobic region of a carrier particle, methods of manufacture, and uses thereof.
|
|
WO/2019/094292A1 |
The present invention includes a pharmaceutical composition and method of making and using comprising one or more thyroid hormones or analogs thereof, wherein a first portion of thyroid hormone is formulated for modified release and a se...
|
|
WO/2019/086720A1 |
The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical comp...
|
|
WO/2019/088010A1 |
The present invention provides a testosterone-containing transdermally administrable preparation having excellent testosterone cutaneous permeability and excellent physical properties. More specifically, the present invention provides a ...
|
